RSS

Hypercholesterolemia

Sanofi and Regeneron Pharmaceuticals have announced positive results from two Phase IIIb/IV ODYSSEY-DM trials evaluating Praluent (alirocumab) in patients with diabetes and hypercholesterolemia. Read more

News

France's Sanofi and US partner Regeneron Pharmaceuticals have reported that the phase 3 trial of drug Praluent reduced cholesterol in 69% of Japanese patients in a phase 3 trial. Read more

News

Sanofi and Regeneron Pharmaceuticals have announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA recommended the approval of the investigational therapy Praluent (alirocumab) injection. Read more

News